[go: up one dir, main page]

MX2016007181A - Medicamentos inhalables. - Google Patents

Medicamentos inhalables.

Info

Publication number
MX2016007181A
MX2016007181A MX2016007181A MX2016007181A MX2016007181A MX 2016007181 A MX2016007181 A MX 2016007181A MX 2016007181 A MX2016007181 A MX 2016007181A MX 2016007181 A MX2016007181 A MX 2016007181A MX 2016007181 A MX2016007181 A MX 2016007181A
Authority
MX
Mexico
Prior art keywords
dry powder
medicament
supply passage
inhalable
measured dose
Prior art date
Application number
MX2016007181A
Other languages
English (en)
Other versions
MX382138B (es
Inventor
Imre Goller Michael
Van Achthoven Erwin
Keegstra Johan
Original Assignee
Pharmachemie Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmachemie Bv filed Critical Pharmachemie Bv
Publication of MX2016007181A publication Critical patent/MX2016007181A/es
Publication of MX382138B publication Critical patent/MX382138B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007—Mechanical counters
    • A61M15/0071—Mechanical counters having a display or indicator
    • A61M15/0078—Mechanical counters having a display or indicator on a strip
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A61M15/0026—Hinged caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/20—Flow characteristics having means for promoting or enhancing the flow, actively or passively

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un inhalador de polvo seco que comprende: un depósito que contiene una formulación de polvo seco y una disposición para suministrar una dosis medida del medicamento desde el depósito; un desaglomerador ciclónico para disgregar aglomerados del medicamento de polvo seco; y un pasaje de suministro para dirigir un flujo de aire de inhalación inducida a través de una boquilla, el pasaje de suministro que se extiende a la dosis medida del medicamento, en donde la formulación comprende un ß2-agonista inhalable que tiene una distribución de tamaño de partícula d10 <1 µm, d50 = 1-3 µm, d90 = 3.5-6 µm y no menos de 99% 10 µm y un portador de lactosa.
MX2016007181A 2013-12-09 2014-11-19 Medicamentos inhalables. MX382138B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1321717.9A GB201321717D0 (en) 2013-12-09 2013-12-09 Inhalable Medicaments
PCT/EP2014/075058 WO2015086278A1 (en) 2013-12-09 2014-11-19 Inhalable medicaments

Publications (2)

Publication Number Publication Date
MX2016007181A true MX2016007181A (es) 2016-10-28
MX382138B MX382138B (es) 2025-03-13

Family

ID=50000403

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016007181A MX382138B (es) 2013-12-09 2014-11-19 Medicamentos inhalables.
MX2021005056A MX395631B (es) 2013-12-09 2014-11-19 Medicamentos inhalables

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021005056A MX395631B (es) 2013-12-09 2014-11-19 Medicamentos inhalables

Country Status (20)

Country Link
US (2) US11071835B2 (es)
EP (3) EP3590499B1 (es)
JP (2) JP6495916B2 (es)
KR (2) KR102207557B1 (es)
CN (1) CN105916491B (es)
AR (1) AR099364A1 (es)
AU (2) AU2014361087B2 (es)
BR (1) BR112016011995A2 (es)
CA (1) CA2930898A1 (es)
DK (2) DK3590499T3 (es)
EA (1) EA034267B1 (es)
ES (2) ES2728076T3 (es)
GB (1) GB201321717D0 (es)
HU (2) HUE044901T2 (es)
IL (1) IL246045B (es)
MX (2) MX382138B (es)
PL (2) PL3079655T3 (es)
TR (1) TR201907647T4 (es)
TW (1) TWI590846B (es)
WO (1) WO2015086278A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
EP3552645A1 (en) * 2016-11-18 2019-10-16 Norton (Waterford) Limited Drug delivery device with electronics
GB201713899D0 (en) * 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
CN116615201A (zh) 2020-08-14 2023-08-18 诺顿（沃特福特）有限公司 丙酸氟替卡松和硫酸沙丁胺醇的可吸入制剂
GB202012742D0 (en) * 2020-08-14 2020-09-30 Norton Waterford Ltd An inhalable medicament
WO2023061508A1 (zh) * 2021-11-29 2023-04-20 康希诺生物股份公司 一种雾化杯及其在雾化吸入给药中的应用
WO2023111637A1 (en) * 2021-12-14 2023-06-22 A. Nattermann & Cie Gmbh Fluid dispensing device
EP4452373A1 (en) * 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Powder inhaler

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6212482B1 (en) * 1998-03-06 2001-04-03 Micron Technology, Inc. Circuit and method for specifying performance parameters in integrated circuits
TWI224513B (en) 2000-06-23 2004-12-01 Norton Healthcare Ltd Dose counter for medicament inhaler
PE20020067A1 (es) 2000-06-23 2002-02-05 Norton Healthcare Ltd Desaglomerador para inhalador de polvo seco accionado por la respiracion
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
KR101179393B1 (ko) * 2004-03-23 2012-09-07 노파르티스 아게 제약 조성물
GB0515584D0 (en) * 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
NZ570162A (en) 2006-01-04 2011-09-30 Boehringer Ingelheim Int Use of tiotropium salts in the treatment of moderate persistent asthma which has the serverity of GINA step 3
BRPI0709872A2 (pt) * 2006-04-03 2011-07-26 Teva Pharma micropartÍculas de drogas
GB0714134D0 (en) 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
WO2009158300A1 (en) 2008-06-26 2009-12-30 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
GB0818476D0 (en) * 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
US10387621B2 (en) * 2009-01-16 2019-08-20 Cerner Innovation, Inc. Matching of vibratory inhalers to patient vocal tract for optimization of particle dispersion
US8834848B2 (en) * 2009-02-04 2014-09-16 Activaero Gmbh Research & Development Flow and volume regulated inhalation for treatment of severe oral corticosteroid-dependent asthma
PL2435024T3 (pl) 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CA2803418A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
SI2600830T1 (en) * 2010-08-03 2018-05-31 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EA201590030A1 (ru) 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
ES2699986T3 (es) * 2013-07-11 2019-02-13 Chiesi Farm Spa Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler

Also Published As

Publication number Publication date
CA2930898A1 (en) 2015-06-18
AR099364A1 (es) 2016-07-20
EA201590734A8 (ru) 2016-11-30
HUE060180T2 (hu) 2023-02-28
HUE044901T2 (hu) 2019-11-28
MX382138B (es) 2025-03-13
KR20160101954A (ko) 2016-08-26
JP6495916B2 (ja) 2019-04-03
CN105916491B (zh) 2022-08-12
WO2015086278A1 (en) 2015-06-18
AU2014361087B2 (en) 2018-04-05
EP4190309A1 (en) 2023-06-07
DK3079655T3 (da) 2019-06-11
TR201907647T4 (tr) 2019-06-21
AU2018204860B2 (en) 2019-07-18
DK3590499T3 (da) 2022-10-31
NZ721338A (en) 2022-03-25
TWI590846B (zh) 2017-07-11
US20210379304A1 (en) 2021-12-09
AU2014361087A1 (en) 2016-07-07
EP3590499B1 (en) 2022-10-05
JP2017505157A (ja) 2017-02-16
CN105916491A (zh) 2016-08-31
JP2019111370A (ja) 2019-07-11
BR112016011995A2 (pt) 2018-07-10
EA201590734A1 (ru) 2015-09-30
IL246045A0 (en) 2016-07-31
AU2018204860A1 (en) 2018-07-19
KR20180101625A (ko) 2018-09-12
PL3079655T3 (pl) 2019-08-30
US11071835B2 (en) 2021-07-27
PL3590499T3 (pl) 2022-11-28
ES2929348T3 (es) 2022-11-28
TW201531314A (zh) 2015-08-16
EP3079655B1 (en) 2019-05-08
ES2728076T3 (es) 2019-10-22
EP3079655A1 (en) 2016-10-19
MX2021005056A (es) 2022-09-15
US20160303337A1 (en) 2016-10-20
EP3590499A1 (en) 2020-01-08
EA034267B1 (ru) 2020-01-23
GB201321717D0 (en) 2014-01-22
KR102207557B1 (ko) 2021-01-26
MX395631B (es) 2025-03-25
JP6946363B2 (ja) 2021-10-06
IL246045B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2016007182A (es) Inhalador de polvo seco.
MX2016007181A (es) Medicamentos inhalables.
Zhou et al. Emerging inhalation aerosol devices and strategies: where are we headed?
CL2016000735A1 (es) Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc.
SA515361055B1 (ar) نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون
JP2014526447A5 (es)
JP2016536043A5 (es)
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
NI201400139A (es) Nueva forma de dosificación y formulación de abediterol
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
PH12013502270A1 (en) Compositions, methods &amp; systems for respiratory delivery of two or more active agents
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
JP2015505541A5 (es)
MX2020003436A (es) Inhalador de polvo seco y metodo de uso.
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
BR112018076760A2 (pt) inalador de pó seco
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
MX2015014338A (es) Composicion farmaceutica que continen budesonida y formoterol.
WO2015027847A3 (zh) 含有奥司他韦羧酸胍基类似体和/或其乙酯制剂的给药方法
TH159392A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด